Source: DailyMed — PRIALT (ziconotide) Prescribing Information
source confidence: High status: Useful updated 2026-06-19
Summary
FDA-approved prescribing information for Prialt (ziconotide), hosted on DailyMed, the NLM's official drug labeling repository. Establishes the drug's composition, approved indication, delivery route, warnings, and initial U.S. approval year (2004).
Useful Claims
- Prialt contains ziconotide, a synthetic equivalent of a naturally occurring conopeptide from Conus magus.
- Initial U.S. approval: 2004.
- Approved indication: management of severe chronic pain in patients who require intrathecal therapy and are refractory to or intolerant of other treatments.
- Administered by continuous intrathecal infusion via an implanted or external pump.
- Carries serious psychiatric and neurological risk warnings.
Reliability Notes
Authoritative government source (NLM/FDA); DailyMed labels are the current, approved regulatory documents for the drug. This is primary for all approved-use and regulatory facts about Prialt. Does not cover the discovery history or commercial licensing chain.